Flagship Ventures Fund IV-Rx, L.P.'s Net Worth

Estimate Recalculated Nov 5, 2024 07:09PM EST

Who is Flagship Ventures Fund IV-Rx, L.P.

Flagship Ventures Fund IV-Rx, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Moderna, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Axcella Health Inc., and Evelo Biosciences, Inc..

SEC CIK

Flagship Ventures Fund IV-Rx, L.P.'s CIK is 0001590973

Past Insider Trading and Trends

No data available

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Moderna, Inc.

Investor

Updated Aug 19, 2020

View Quote Details


Form 4	-36.29%	-11.05M	—	—	Aug 19, 2020	32.97M	Disposition	—	Aug 17
Form 4	-1.71%	-1.00M	$68.22	-$68.22M	May 26, 2020	70.17M	Sale	—	May 21 - May 22
Form 4	-29.46%	-12.28M	—	—	May 13, 2020	42.26M	Disposition	—	May 11
Form 4	-5.75%	-9.67M	$18.87	-$8.20M	Dec 11, 2019	170.63M	Sale	—	Dec 09 - Dec 11
Form 4	—	—	—	—	Dec 13, 2018	58.81M	Options	—	Dec 11
Form 3	—	—	—	—	Dec 07, 2018	11.46M	—	—	—

Showing 6 results

Seres Therapeutics, Inc.

Investor

Updated Nov 25, 2020

View Quote Details


Form 4	-39.84%	-7.91M	—	—	Nov 25, 2020	15.05M	Disposition	—	Nov 23
Form 4	-12.02%	-2.00M	$27.60	-$27.60M	May 27, 2016	14.64M	Sale	—	May 25
Form 4	0.13%	15.00K	—	—	Jun 29, 2015	14.70M	Options	—	Jun 25 - Jun 26
Form 3	—	—	—	—	Jun 25, 2015	3.06M	—	—	—

Showing 4 results

Editas Medicine, Inc.

Investor

Updated Aug 15, 2016

View Quote Details


Form 4	-30.97%	-1.55M	—	—	Aug 15, 2016	3.50M	Disposition	—	Aug 11
Form 4	-61.54%	-7.93M	—	—	Feb 09, 2016	4.96M	Options	—	Feb 08
Form 3	—	—	—	—	Feb 02, 2016	—	—	—	—

Showing 3 results

Rubius Therapeutics, Inc.

Investor

Updated Jul 23, 2018

View Quote Details


Form 4	—	—	—	—	Jul 23, 2018	56.27M	Options	—	Jul 20
Form 3	—	—	—	—	Jul 17, 2018	5.00M	—	—	—

Showing 2 results

Syros Pharmaceuticals, Inc.

Investor

Updated Aug 21, 2017

View Quote Details


Form 4	-35.64%	-1.66M	—	—	Aug 21, 2017	3.25M	Disposition	—	Aug 17
Form 4	-43.85%	-11.13M	$12.50	$5.00M	Jul 07, 2016	14.47M	Buy-Options	—	Jul 06
Form 3	—	—	—	—	Jun 29, 2016	213.33K	—	—	—

Showing 3 results

Eleven Biotherapeutics, Inc.

Investor

Updated Sep 26, 2016

View Quote Details


Form 4	-14.78%	-443.42K	$3.15	-$1.40M	Sep 26, 2016	4.39M	Sale	—	Sep 22 - Sep 23
Form 4	-9.62%	-386.34K	$3.48	-$1.43M	Sep 21, 2016	5.46M	Sale	—	Sep 19 - Sep 21
Form 4	-1.68%	-46.69K	$4.17	-$195.12K	Sep 16, 2016	4.56M	Sale	—	Sep 14 - Sep 15
Form 4	-1.93%	-129.50K	$4.57	-$588.32K	Sep 08, 2016	6.58M	Sale	—	Sep 06 - Sep 07
Form 4	-67.78%	-13.40M	$10.00	$3.79M	Feb 13, 2014	6.37M	Buy-Options	—	Feb 11
Form 3	—	—	—	—	Feb 05, 2014	419.85K	—	—	—

Showing 6 results

Axcella Health Inc.

Investor

Updated Mar 18, 2022

View Quote Details


Form 4	72.21%	6.32M	$1.91	$12.07M	Mar 18, 2022	18.87M	Purchase	—	Mar 16
Form 4	76.74%	3.80M	$4.75	$18.05M	May 20, 2020	12.55M	Purchase	—	May 18
Form 4	-17.91%	-4.16M	$20.00	—	May 15, 2019	21.78M	Buy-Options	—	May 13
Form 3	—	—	—	—	May 08, 2019	2.71M	—	—	—

Showing 4 results

Evelo Biosciences, Inc.

Investor

Updated Jun 01, 2022

View Quote Details


Form 4	288.55%	27.40M	$1.46	$40.00M	Jun 01, 2022	50.43M	Purchase	—	May 27
Form 4	1.39%	130.00K	$15.00	$1.95M	Feb 04, 2021	23.03M	Purchase	—	Feb 02
Form 4	99.33%	4.67M	$3.75	$17.50M	Jul 01, 2020	22.90M	Purchase	—	Jun 29
Form 4	-71.05%	-44.74M	$16.00	$4.50M	May 15, 2018	18.23M	Buy-Options	—	May 11
Form 3	—	—	—	—	May 08, 2018	3.33M	—	—	—

Showing 5 results